Conatus is leveraging its broad expertise in caspase inhibition supplemented by in-licensing to develop an independent product pipeline

  • We are exploring the potential of a retained compound, IDN-7314, in primary sclerosing cholangitis (PSC)
    • IDN-7314 has US and EU exclusivity through orphan drug designations
    • IDN-7314 has generated positive preclinical proof of concept data in PSC
  • We are optimizing new caspase inhibitors for other organ systems
    • Potential internal development in GI and lung diseases
    • Potential partnering in cardiovascular, central nervous system and kidney diseases

  • We are evaluating near-term in-licensing opportunities consistent with our developmental, clinical and regulatory expertise
    • Actively exploring in-licensing of clinical stage drug candidates for internal development in GI diseases
​ ​